Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils' but Impaired Monocytes' and Dendritic Cells' Responsiveness.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ genetics
COVID-19
Cells, Cultured
Coronavirus Infections
/ blood
Cytokines
/ genetics
Dendritic Cells
/ immunology
Female
Humans
Immunity, Innate
Immunophenotyping
Male
Middle Aged
Monocytes
/ immunology
Neutrophils
/ immunology
Pandemics
Pneumonia, Viral
/ blood
COVID-19
IFN alpha
PD-L1
SARS-CoV-2
cytokine storm
degranulation
dendritic cells
innate immunity
monocytes
neutrophils
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
29 09 2020
29 09 2020
Historique:
received:
04
09
2020
revised:
23
09
2020
accepted:
29
09
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
21
10
2020
Statut:
epublish
Résumé
COVID-19, caused by SARS-CoV-2 virus, emerged as a pandemic disease posing a severe threat to global health. To date, sporadic studies have demonstrated that innate immune mechanisms, specifically neutrophilia, NETosis, and neutrophil-associated cytokine responses, are involved in COVID-19 pathogenesis; however, our understanding of the exact nature of this aspect of host-pathogen interaction is limited. Here, we present a detailed dissection of the features and functional profiles of neutrophils, dendritic cells, and monocytes in COVID-19. We portray the crucial role of neutrophils as drivers of hyperinflammation associated with COVID-19 disease via the shift towards their immature forms, enhanced degranulation, cytokine production, and augmented interferon responses. We demonstrate the impaired functionality of COVID-19 dendritic cells and monocytes, particularly their low expression of maturation markers, increased PD-L1 levels, and their inability to upregulate phenotype upon stimulation. In summary, our work highlights important data that prompt further research, as therapeutic targeting of neutrophils and their associated products may hold the potential to reduce the severity of COVID-19.
Identifiants
pubmed: 33003471
pii: cells9102206
doi: 10.3390/cells9102206
pmc: PMC7600406
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : AZV NU20-05-00320
Pays : International
Références
Hong Kong Med J. 2012 Aug;18 Suppl 3:28-30
pubmed: 22865220
Biofactors. 2019 Nov;45(6):930-943
pubmed: 31454114
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Cells. 2020 Jun 02;9(6):
pubmed: 32498376
ACS Nano. 2018 Feb 27;12(2):1250-1261
pubmed: 29370526
J Clin Immunol. 2020 Jan;40(1):165-178
pubmed: 31760574
Curr Opin Virol. 2016 Feb;16:31-40
pubmed: 26812607
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Cell Host Microbe. 2020 Jun 10;27(6):879-882.e2
pubmed: 32359396
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
J Virol. 2014 Jun;88(12):6672-89
pubmed: 24696476
J Virol. 2007 Aug;81(16):8692-706
pubmed: 17537853
Arch Med Res. 2020 Apr;51(3):282-286
pubmed: 32229155
PLoS One. 2017 Jan 23;12(1):e0170516
pubmed: 28114346
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Mol Oncol. 2019 Apr;13(4):873-893
pubmed: 30628173
J Biol Chem. 2009 Jun 12;284(24):16202-9
pubmed: 19380580
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Front Immunol. 2012 Aug 24;3:263
pubmed: 22936934
J Autoimmun. 2019 Dec;105:102294
pubmed: 31256920
Ann Rheum Dis. 2014 Dec;73(12):2199-207
pubmed: 24013727
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
Blood. 2003 Oct 1;102(7):2660-9
pubmed: 12829592
Front Immunol. 2020 Jul 03;11:1665
pubmed: 32719688
J Immunol. 2010 Mar 15;184(6):3284-97
pubmed: 20164424
Immunology. 2020 Sep 1;:
pubmed: 32870529
Front Immunol. 2020 Feb 17;11:122
pubmed: 32132993
J Virol. 2014 Jan;88(2):913-24
pubmed: 24198408
PLoS One. 2018 Dec 31;13(12):e0205886
pubmed: 30596665
Dig Liver Dis. 2020 Aug;52(8):895-904
pubmed: 32620521
Eur Respir J. 2020 Aug 28;:
pubmed: 32859680
Nat Med. 2006 Nov;12(11):1301-9
pubmed: 17041596
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Blood. 2017 Mar 9;129(10):1343-1356
pubmed: 28053192
Blood. 2008 Sep 1;112(5):2028-34
pubmed: 18544685
Immunity. 2003 Oct;19(4):583-93
pubmed: 14563322
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Front Cell Infect Microbiol. 2019 Jun 13;9:207
pubmed: 31263684
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Crit Care. 2014 Oct 21;18(5):568
pubmed: 25331176
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Eur J Clin Pharmacol. 2020 Nov;76(11):1501-1504
pubmed: 32583353
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Cancer Metastasis Rev. 2020 Sep;39(3):933-952
pubmed: 32435939
Immunity. 2020 Oct 13;53(4):864-877.e5
pubmed: 32791036
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Cell Mol Immunol. 2016 Jan;13(1):3-10
pubmed: 26189369
Antiviral Res. 2020 Jun;178:104791
pubmed: 32275914
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677